Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. | Ivonescimab plus chemotherapy - (AK112-201) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Summit Therapeutics Inc. | Ezutromid | Duchenne muscular dystrophy | Phase 2 | Trial Discontinued | Oral | Genetic Disorder |
| Supernus Pharmaceuticals Inc. | SPN-810 | Impulsive Aggression in ADHD | Phase 3 | Trial Completed | Oral | Psychiatric |
| Supernus Pharmaceuticals Inc. | SPN-604 | Bipolar depression | Phase 3 | Trial Discontinued | Oral | Psychiatric |
| Supernus Pharmaceuticals Inc. | SPN-810 (P302) | Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Trial Discontinued | Oral | Psychiatric |
| Supernus Pharmaceuticals Inc. | SAGE-217 - (SHORELINE) | Major Depressive Disorder (MDD) | Phase 3 | Data Released | oral | Psychiatric |
| Supernus Pharmaceuticals Inc. | SPN-820 | Treatment-resistant depression | Phase 2b | Data Released | Oral | Psychiatric |
| Supernus Pharmaceuticals Inc. | Dalzanemdor (SAGE-718) - (DIMENSION) | Huntington's disease (HD) | Phase 2 | Data Released | Oral | Neurology |
